The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2017 | How can we overcome ibrutinib resistance?
Meixiao Long, MD from the Ohio State University, Columbus, OH discusses leukemia cell resistance to ibrutinib. He believes in a multimodal combination approach with immunotherapy to bypass ibrutinib resistance, for e.g. tumour vaccines or checkpoint blockade, which can hopefully lead to durable response rates. This interview was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY.
